Hyland Paula L, Pfeiffer Ruth M, Rotunno Melissa, Hofmann Jonathan N, Liu Chin-San, Cheng Wen-Ling, Yuenger Jeff, Lan Qing, Tucker Margaret A, Goldstein Alisa M, Yang Xiaohong R
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Vascular and Genomic Research Center, Changhua Christian Hospital, Changhua 500, Taiwan.
J Carcinog Mutagen. 2014 Jun 26;2014(Suppl 4). doi: 10.4172/2157-2518.S4-006.
Quantitative changes in mitochondrial DNA (mtDNA) have been associated with the risk of a number of human cancers; however, the relationship between constitutive mtDNA copy number in blood and the risk of familial cutaneous malignant melanoma (CMM) has not been reported. We measured mtDNA copy number using quantitative PCR in blood-derived DNA from 136 CMM cases and 302 controls in 53 melanoma-prone families (23 segregating germline mutations). MtDNA copy number did not vary by age, sex, pigmentation characteristics, or CMM status. However, germline mutation carriers had significantly higher mean mtDNA copy number compared to non-carriers, particularly among CMM cases (geometric mean mtDNA copy number of 144 and 111 for carrier versus non-carrier, respectively; P= 0.02). When adjusting for age, sex, and familial correlation, having increasing mtDNA copy number was significantly associated with mutation status among CMM cases (OR=1.47, =0.024). In particular, individuals with specific mutations with the potential to inactivate or reduce the level of the p16-INK4 reactive oxygen species (ROS) protective function had significantly increased mtDNA copy number levels (P=0.035). Future research in prospective studies is required to validate these findings and to further investigate mtDNA copy number in both blood and melanoma tissues in relation to CMM risk and mutation status.
线粒体DNA(mtDNA)的定量变化与多种人类癌症的风险相关;然而,血液中组成型mtDNA拷贝数与家族性皮肤恶性黑色素瘤(CMM)风险之间的关系尚未见报道。我们使用定量PCR测量了来自53个黑色素瘤易感家族(23个分离种系突变)的136例CMM病例和302例对照的血液来源DNA中的mtDNA拷贝数。mtDNA拷贝数不因年龄、性别、色素沉着特征或CMM状态而变化。然而,与非携带者相比,种系突变携带者的平均mtDNA拷贝数显著更高,尤其是在CMM病例中(携带者与非携带者的几何平均mtDNA拷贝数分别为144和111;P = 0.02)。在调整年龄、性别和家族相关性后,mtDNA拷贝数增加与CMM病例中的突变状态显著相关(OR = 1.47,P = 0.024)。特别是,具有特定突变且有可能使p16-INK4活性氧(ROS)保护功能失活或降低水平的个体,其mtDNA拷贝数水平显著增加(P = 0.035)。未来需要在前瞻性研究中进行进一步研究,以验证这些发现,并进一步研究血液和黑色素瘤组织中的mtDNA拷贝数与CMM风险和突变状态的关系。